The products discussed herein are available only upon prescription from a medical doctor or a qualified medical professional
PRODUCT DEVELOPMENT
1 x 6 1 x 3 30
On October 25, the U
In March 2019, a third possible carcinogen - N-Methylnitrosobutyric acid (NMBA) was discovered in some batches of losartan from Hetero Labs Limited, a generic drug maker located in India, prompting yet another expansion of the drug's recall
Initial Notification : Letter: Unique Ingredient Identifier: 3ST302B24A: Drug Application Number: ANDA078232; Structured Product Labeling (SPL ID) b20b3678-bd1a-4ca6-9f79-b4a27aa003bd Structured Product Labeling (SPL Set ID) e5886220-43b7-46e1-9034-5242ba245bd1 Similar To: Recall D-0180-2022 Recall D-0147-2022 There are no anticipated shortages of irbesartan-containing and losartan-containing products in the UK as a result of this recall
Losartan Potassium Tablets USP 25mg, 50mg, 100mg
5 mg, bottle, 90 count, NDC 68180-0215-09 Estimated Resupply Dates Teva has all losartan and hydrochlorothiazide tablet presentations on back order and the company estimates a release date in late-March 2024
High blood pressure adds to the workload of the heart and arteries
USA: Chlorzoxazone: 4/28/22 Glenmark: Naproxen: 4/28/22 Glenmark: Zonisamide: Recall Number: D-0789-2022: Event ID: 90001: Distribution: Nationwide within the U
There is no evidence that doses greater than 3000 mg/day confer additional benefit
5 mg and losartan potassium and You may report side effects to FDA at 1-800-FDA-1088
Revised: January 2019 ID#: 258001
has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets
Lupin Pharmaceuticals Inc
Class 2 Recall: Using the drug may cause temporary or medical reversible adverse health consequences, the probability of serious adverse health consequences is remote
Initial Notification : Letter: Unique Ingredient Identifier: 0J48LPH2TH 3ST302B24A: Drug Application Number: ANDA078245; Structured Product Labeling (SPL ID) d6b52688-486b-4256-b9f7-667ec6163dd3 Structured Product Labeling (SPL Set ID) ee1eaaf6-050b-48af-942b-5e3451edc164 Similar To: Recall D-0180-2022 Recall D-0147-2022 FDA expands recall on blood pressure drug valsartan due to probable carcinogen 02:42 Another pharmaceutical company is recalling blood pressure medication after detecting trace amounts of a cancer USA TODAY
In March 2022, Pfizer (NYSE:PFE) recalled five lots of Accupril-branded quinapril tablets as a result of elevated levels of the nitrosamine N-nitroso-quinapril
This can damage the blood vessels of the brain, heart, and kidneys Blood Pressure Drug Recall Due to Carcinogenic Impurity
Irbesartan tablet USP is designed to treat Lupin Pharmaceuticals is voluntarily recalling certain dosages of irbesartan tablets and irbesartan and hydrochlorothiazide tablets distributed in 30- and
In December 2018, Torrent Pharmaceuticals began a voluntary recall of losartan due to the presence of small traces of known carcinogens
Accuretic and its two generic
Losartan potassium tablet is a prescription medicine called an angiotensin receptor blocker (ARB)
When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide as soon as
Recalls can be grouped as Class 1, 2 or 3
Losartan and Hydrochlorothiazide oral tablet, Rising Pharmaceuticals, 100 mg/ 12
5mg; and 143 lots of Losartan Potassium and Hydrochlorothiazide tablets USP, 100mg/25mg to the retail level
5mg, 100/25mgPack Size: 30, 90 NDC#: 68180-215-06, 68180-215-09, 68180-216-06, 68180-216-09, 68180-217-06, 68180-217-09RLD/Brand Name: Hyzaar® TE Rating: AB Therapeutic Category: Angiotensin II Receptor antagonist w/ Diuretic
We're an innovative, transnational pharmaceutical company with a legacy of excellence in the U
The last Recall Enforcement Report for Losartan Potassium with NDC 68180-377 was initiated on 03-31-2022 as a Class II recall and it is currently terminated
1 x 6 1 x 3 30
arm will pull one lot of 10 mg lisinopril tablets in the United States, citing 20 mg tablets found in at least one bottle
Cadista has temporarily discontinued losartan tablets due to issues with obtaining active ingredient
The product's dosage form is tablet and is administered via oral form